TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04893317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation in the ventricles with the Adagio Medical VT Cryoablation System
Description: The Adagio Medical VT Cryoablation System is indicated for the treatment of monomorphic ventricular tachycardia by ablation of arrhythmogenic tissue that drives and maintains these arrhythmias
Study: NCT05959655

Intervention type: DEVICE
Intervention: Glean Urodynamics System
Description: Wireless, catheter-free urodynamics system
Study: NCT06658938

Intervention type: DRUG
Group type: OTHER
Intervention: Blinatumomab
Description: Beginning 3 months after transplantation, 1 cycle of blinatumomab was performed every 3 months for a total of 4 maintenance cycles.~Dosage of blinatumomab: 9 ug/d D1-4, 28 ug/d D5-14
Study: NCT06018077

Intervention type: BEHAVIORAL
Intervention: Dietary İntake, Biochemical parameters, Antropometric measuruments
Description: Nutritional status of individuals will be evaluated with a 24-hour retrospective food consumption record and food consumption frequency questionnaire. After 8-12 hours of fasting, body composition analysis will be performed and within the scope of anthropometric measurements, body weight, height length, BMI measurements will be taken. Then, venous blood will be taken from the participants C-reactive protein (CRP), albumin and chemerin level will be analyzed.

Intervention type: BEHAVIORAL
Intervention: Dietary İntake, Biochemical parameters, Antropometric measuruments
Description: Nutritional status of individuals will be evaluated with a 24-hour retrospective food consumption record and food consumption frequency questionnaire. After 8-12 hours of fasting, body composition analysis will be performed and within the scope of anthropometric measurements, body weight, height length, BMI measurements will be taken. Then, venous blood will be taken from the participants C-reactive protein (CRP), albumin and chemerin level will be analyzed.
Study: NCT05509790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally.
Study: NCT05027347

Intervention type: DIAGNOSTIC_TEST
Intervention: plasma circulating tumor DNA
Description: A liquid biopsy assay for identification of tumor derived mutations in plasma of gastric cancer
Study: NCT05793684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period B
Description: Week 1: AD816 low dose; Week 2: AD816 high dose
Study: NCT06093308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuremidevir Hydrobromide Tablets
Description: Multiple administration, oral administration after meals, D1: 0.6g, twice a day; D2-D5: 0.3g, twice a day; D6: 0.3g, administered once in the morning
Study: NCT05262777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GP0112
Description: Injectable gel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Lyft Lidocaine
Description: Injectable gel
Study: NCT06485167

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIFEM- chair
Description: The intervention consists of pelvic floor training combined with high-intensity electromagnetic energy treatment (HIFEM®). This includes six HIFEM® treatments (each lasting 28 minutes) with one session per week over six weeks. The woman completes a voiding diary before treatment and one week (±7 days) after treatment. She sits fully clothed on the HIFEM chair.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HIFEM- chair
Description: The intervention consists of pelvic floor training combined with high-intensity electromagnetic energy treatment (HIFEM®). This includes six HIFEM® treatments (each lasting 28 minutes) with one session per week over six weeks. The woman completes a voiding diary before treatment and one week (±7 days) after treatment. She sits fully clothed on the HIFEM chair.
Study: NCT05793684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period C
Description: Week 1: Placebo + Placebo; Week 2: Placebo + Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period C
Description: Week 1: Placebo + Placebo; Week 2: Placebo + Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period C
Description: Week 1: Placebo + Placebo; Week 2: Placebo + Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period C
Description: Week 1: Placebo + Placebo; Week 2: Placebo + Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period C
Description: Week 1: Placebo + Placebo; Week 2: Placebo + Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period C
Description: Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
Study: NCT05675397

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: donor human milk
Description: Pasteurized preterm donor milk (PDM) versus term donor milk (TDM) will be provided to the study population following randomization, as supplementary to mother's own milk (MOM) or as alternative feeding

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: donor human milk
Description: Pasteurized preterm donor milk (PDM) versus term donor milk (TDM) will be provided to the study population following randomization, as supplementary to mother's own milk (MOM) or as alternative feeding
Study: NCT05280782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 Galmydar
Description: Single intravenous injection of the PET radiotracer 68Ga-Galmydar.
Study: NCT04517227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter Hepatic Arterial Chemoembolization (TACE)
Description: TACE techniques have been described in the NCCN and ESMO-ESDO guidelines, including cTACE and DEB-TACE.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: In this study, thermal ablation could be conducted with radiofrequency (RFA) or microwave (MWA).
Study: NCT05950555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: We used 0.9% isotonic sodium chloride.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: We used the vial containing 200 mcg/2 ml i.v. concentrated infusion solution in 100 ml of 0.9% isotonic sodium chloride.
Study: NCT05466682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)
Description: Relaxation technique delivered via RELAXaHEAD app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitored Usual Care (MUC)
Description: Standard of care plus daily symptom reporting using the RELAXaHEAD app electronic diary.
Study: NCT05950555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: We used 500 mg/10 ml solution for injection in 0.9% isotonic sodium chloride.
Study: NCT04039789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project active legs
Description: Home program of exercises of lower extremities includes the performance of 4 exercises of lower extremities of progressive difficulty that must be carried out at home 5 days a week, twice a day and walking progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Evaluation, cleaning, debridement, topical treatment (moist healing) and compressive therapy according to the recommendations for the treatment of chronic cutaneous ulcers of the Community of Madrid.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Evaluation, cleaning, debridement, topical treatment (moist healing) and compressive therapy according to the recommendations for the treatment of chronic cutaneous ulcers of the Community of Madrid.
Study: NCT06790342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cystine
Description: Used for smoking cessation and alcohol reduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cystine
Description: Used for smoking cessation and alcohol reduction
Study: NCT06166888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK131
Description: AK131 is an anti-PD-1 and CD73 bispecific antibody
Study: NCT02556970

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single port VATS
Description: Performing video-assisted thorascopic surgery through a single port

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1g intraoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1g intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 75mg intraoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 75mg intraoperatively
Study: NCT05990153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clinical practice drug treatment
Description: drug treatment according to the medical indications of clinical practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Description: The manual therapy consists of the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
Study: NCT02556970

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Camera (5mm diameter 30 degree videothoracoscope)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Camera (5mm diameter 30 degree videothoracoscope)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forceps grasper
Study: NCT06790342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Smoke Free
Description: An 8 session tailored behavioral treatment for smoking cessation and alcohol reduction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Smoke Free
Description: An 8 session tailored behavioral treatment for smoking cessation and alcohol reduction
Study: NCT02556970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forceps grasper

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Levobupivicaine intercostal nerve block
Description: Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
Study: NCT05990153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise (TE)
Description: The ET consists of an initial phase of aerobic exercise (cyclette), subsequently the intervention foresees exercises for the cervical ROM, stretching exercises of the cervical and scapulothoracic muscles and muscle strengthening exercises (isometric, concentric and eccentrics of the cervical musculature).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise (TE)
Description: The ET consists of an initial phase of aerobic exercise (cyclette), subsequently the intervention foresees exercises for the cervical ROM, stretching exercises of the cervical and scapulothoracic muscles and muscle strengthening exercises (isometric, concentric and eccentrics of the cervical musculature).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise (TE)
Description: The ET consists of an initial phase of aerobic exercise (cyclette), subsequently the intervention foresees exercises for the cervical ROM, stretching exercises of the cervical and scapulothoracic muscles and muscle strengthening exercises (isometric, concentric and eccentrics of the cervical musculature).
Study: NCT05940753

Intervention type: OTHER
Intervention: Survey about travel willingness regarding cancer treatment and follow-up
Description: No intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient.
Study: NCT02556970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Levobupivicaine intercostal nerve block
Description: Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
Study: NCT06348758

Intervention type: OTHER
Intervention: questionnaire
Description: E-Questionnaire will be sent to the students
Study: NCT04742036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Part A Cycle 0: Single dose 480 mg(3 x 160 mg tablets) on Day 1 of Cycle 0 Cycle 1 (monotherapy): 480 mg(3 x 160 mg tablets) twice daily given on an intermittent weekly dosing schedule (4 days on, 3 days off for 7 days) Part B Cycle 2 (in combination therapy with paclitaxel): 400 mg (2 x 200 mg tablets) twice daily given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Capivasertib treatment will continue until disease progression, unacceptable toxicity or the participant requests to stop treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Part B Cycle 2: Patients will receive 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Paclitaxel treatment will continue for at least 6 cycles, unless the participant experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel, or disease progression.
Study: NCT04775394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Bronchoalveolar lavage, mucosal biopsy and bronchial brushes during bronchoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Bronchoalveolar lavage, mucosal biopsy and bronchial brushes during bronchoscopy
Study: NCT05137275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-5T4 CAR-raNK Cells
Description: In the 3+3 dose escalation study, the minimum initial dose is 3.0×10\^9 cells and then escalate to 6.0× 10\^9 and 9.0× 10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 3\\8 of each cycle. In dose extension study, the initial dose will be determined by RP2D determined by the results of dose escalation study, and the other intervention methods are consistent.
Study: NCT05051033

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve repair
Description: Patients who are randomized to the surgical arm will undergo mitral surgery. Mitral surgery will be conducted using general anesthesia and cardiopulmonary bypass. Mitral surgery may be performed via a sternotomy or a right thoracotomy approach with or without robotic assistance. Standard techniques commonly include a ring or band annuloplasty to correct and prevent annular dilatation; leaflet prolapse and redundancy may be corrected by leaflet resection techniques and / or chordal reconstruction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter edge-to-edge repair
Description: Patients will be treated with a commercially-approved edge-to-edge mitral repair device. The steerable guide catheter (guide) is inserted into the femoral vein and advanced across the inter-atrial septum using image guided puncture. Fluoroscopic and echocardiographic guidance will be used to visualize the devices and assess the repair. The guide is positioned over the MV and the clip/clasp delivery system is inserted into the guide and positioned over the MV in accordance with the manufacturer's instructions. The delivery catheter is advanced until the clip/clasp emerges from the tip of the guide into the left atrium. The catheter is manipulated using the control handle until the clip/clasp is correctly oriented with respect to the line of coaptation of the mitral valve. The clip/clasp is opened, and advanced across the mitral valve into the left ventricle then pulled back to grasp the leaflets.
Study: NCT06269588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexpowder
Description: Endoscopic hemostasis
Study: NCT05581628

Intervention type: DIAGNOSTIC_TEST
Intervention: Pain location inventory (PLI)
Description: PLI is obtained by questioning the pain in 28 regions in the last 7 days. Total score is between 0-28

Intervention type: DIAGNOSTIC_TEST
Intervention: Symptom Impact Questionnaire (SIQR)
Description: The SIQR score includes a total of 10 different evaluations in the last 7 days, including pain, energy, stiffness, sleep, depression, memory problems, anxiety, sensitivity to touch, balance problems, sensitivity to loud sounds-bright light-smells-cold. Each item is scored between 0-10 and the total score is obtained between 0-100. This total score is divided by 2 to get the SIQR score

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibromyalgia Impact Questionnaire (FIQ)
Description: FIQ measures 10 different features, including physical function, well-being, absenteeism, difficulty at work, pain, fatigue, morning fatigue, stiffness, anxiety and depression. With the exception of the well-being trait, low scores indicate recovery or less affliction. The maximum possible score of each sub-title is 10. Thus, the total maximum score is 100.
Study: NCT06350357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: punching closure
Description: The hole clamping and the grooves hold the metal clips better

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional clipping
Description: Metal lip closure is one of the most commonly used closure methods
Study: NCT06163729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy
Description: Durg：Camrelizumab: 200mg, iv, d1, q3w Durg ：Oxaliplatin, 100mg/m2 , iv, d1, q3w Durg ：Paclitaxel(Albumin Bound), 125mg/m2, iv, d1, d8, q3w； Durg ：Radiotherapy, PGTV：45.1Gy/2.05Gy/ 22f； PTV：40.04Gy/1.82Gy/ 22f；Five days a week for more than four weeks
Study: NCT05686850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-Flow Oxygen
Description: Humidified and heated oxygen with a gas flow at least 50 L/min through nasal cannula

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Flow Oxygen
Description: Humidified and heated oxygen with a gas flow at least 50 L/min through nasal cannula

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation
Description: NIV will be carried out in pressure-support mode with a minimal pressure-support level of 5 cmH2O targeting a tidal volume around 6 to 8 mL/kg of predicted bodyweight, a positive end-expiratory pressure (PEEP) level at least 8 cm H2O, and FiO2 adjusted to obtain adequate oxygenation
Study: NCT05846204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: The PMR exercise, which includes the systematic relaxation of the main muscle groups of the body aimed at physical and psychological relaxation, was applied twice a day, every weekday, for eight weeks.~DB exercises training was given to the patients in this group individually by face-to-face interview. During the application, the importance of deep and comfortable breathing was explained and correct breathing technique was taught.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep Breathing Exercise Group-DBE
Description: Breathing exercise is an exercise to improve breathing and functional performance. deep breathing exercise; It is a nursing intervention that helps to increase the function of respiratory muscles and improve ventilation and oxygenation.
Study: NCT05999929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Support System
Description: The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
Study: NCT06321276

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shockwave therapy
Description: Extracorporeal shock wave therapy (ESWT) is a non-invasive procedure that uses single-pulse acoustic waves generated outside the body and focused on a specific area of the body. Shock waves promote axonal regeneration of peripheral nerves through various molecular reactions. Although the anti-nociceptive mechanisms of ESWT have not yet been elucidated, ESWT may produce analgesia through biochemical changes in the nerve fiber itself and reduce inflammation of soft tissues.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shockwave therapy
Description: Extracorporeal shock wave therapy (ESWT) is a non-invasive procedure that uses single-pulse acoustic waves generated outside the body and focused on a specific area of the body. Shock waves promote axonal regeneration of peripheral nerves through various molecular reactions. Although the anti-nociceptive mechanisms of ESWT have not yet been elucidated, ESWT may produce analgesia through biochemical changes in the nerve fiber itself and reduce inflammation of soft tissues.
Study: NCT06267807

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dynamic contrast-enhanced lymphangiography
Description: The subject is placed supine on a detachable MR imaging table, outside the scanning room. Both inguinal regions are prepared under sterile conditions. Using Ultrasound guidance, the thoracic duct outlet at the left venous angle is identified. Under US guidance, a small 25 gauge needle is placed at the corticomedullar junction of an inguinal lymph node on each side. The needle position is confirmed and checked that there is no extravasation at saline injection under US visualization. The subject is then transferred to the MR imaging machine. First, pre-contrast imaging is performed, this takes around 20 minutes.
Study: NCT04531397

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACEI treatment
Description: ACEI, will be given once daily based on body weight (0.2mg/kg/d-0.6mg/kg/d，max 20mg/d), for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin+ACEI treatment
Description: Dapagliflozin will be given 10 mg/day (weight\>30kg) or 5mg/day (weight≤30kg), for 24 weeks ACEI, will be given based on body weight (max 20mg/d), for 24 weeks.